Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2026)

Kymera Therapeutics (KYMR) has reported Long-Term Investments for 7 consecutive years, with $894.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 186.46% year-over-year to $894.7 million; the TTM figure through Mar 2026 stood at $894.7 million (up 186.46% YoY), while the FY2025 annual figure was $771.2 million, up 112.91% from the prior year.
• Long-Term Investments rose to $894.7 million in Q1 2026 per KYMR's latest filing, from $771.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $894.7 million in Q1 2026 and bottomed at $61.4 million in Q1 2023.
• Historically, Long-Term Investments has averaged $273.7 million across 5 years, with a median of $192.4 million in 2024.
• Annual changes were most pronounced in 2023 — Long-Term Investments slumped 59.67% — and 2024, when it jumped 489.58%.
• Kymera Therapeutics' Long-Term Investments stood at $152.3 million in 2022, then tumbled by 59.67% to $61.4 million in 2023, then surged by 489.58% to $362.2 million in 2024, then surged by 112.91% to $771.2 million in 2025, then grew by 16.02% to $894.7 million in 2026.
• Business Quant data shows KYMR's Long-Term Investments at $894.7 million in Q1 2026, $771.2 million in Q4 2025, and $473.1 million in Q3 2025.